Chenguang Biotech Group (300138) — Working Capital to Net Assets Ratio
Chenguang Biotech Group (300138) has a Working Capital to Net Assets ratio of 47.6% as of September 2025. Working capital of CN¥1.61 Billion (current assets of CN¥5.78 Billion minus current liabilities of CN¥4.16 Billion) is measured against net assets of CN¥3.39 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Chenguang Biotech Group balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Chenguang Biotech Group Working Capital to Net Assets (2007–2024)
This chart shows how Chenguang Biotech Group's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 47.6%, reflecting working capital of CN¥1.61 Billion against net assets of CN¥3.39 Billion CNY. Check 300138 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Chenguang Biotech Group (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Chenguang Biotech Group from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Chenguang Biotech Group stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 70.1% | CN¥2.21 Billion | CN¥3.15 Billion | CN¥6.81 Billion | CN¥4.60 Billion | ▲ +1.8 pp |
| 2023 | 68.4% | CN¥2.41 Billion | CN¥3.53 Billion | CN¥6.37 Billion | CN¥3.95 Billion | ▲ +0.9 pp |
| 2022 | 67.5% | CN¥2.17 Billion | CN¥3.21 Billion | CN¥4.93 Billion | CN¥2.76 Billion | ▲ +21.0 pp |
| 2021 | 46.5% | CN¥1.29 Billion | CN¥2.78 Billion | CN¥3.98 Billion | CN¥2.68 Billion | ▼ -25.6 pp |
| 2020 | 72.2% | CN¥1.49 Billion | CN¥2.06 Billion | CN¥2.91 Billion | CN¥1.43 Billion | ▲ +28.6 pp |
| 2019 | 43.6% | CN¥759.09 Million | CN¥1.74 Billion | CN¥3.19 Billion | CN¥2.43 Billion | ▼ -1.4 pp |
| 2018 | 45.0% | CN¥782.90 Million | CN¥1.74 Billion | CN¥2.34 Billion | CN¥1.56 Billion | ▼ -6.0 pp |
| 2017 | 51.0% | CN¥828.26 Million | CN¥1.62 Billion | CN¥2.02 Billion | CN¥1.20 Billion | ▼ -5.0 pp |
| 2016 | 56.0% | CN¥853.31 Million | CN¥1.52 Billion | CN¥1.77 Billion | CN¥912.30 Million | ▼ -3.0 pp |
| 2015 | 58.9% | CN¥840.83 Million | CN¥1.43 Billion | CN¥1.35 Billion | CN¥506.92 Million | ▲ +13.4 pp |
| 2014 | 45.6% | CN¥459.54 Million | CN¥1.01 Billion | CN¥904.53 Million | CN¥444.99 Million | ▲ +2.6 pp |
| 2013 | 43.0% | CN¥425.86 Million | CN¥990.39 Million | CN¥1.01 Billion | CN¥583.33 Million | ▼ -3.5 pp |
| 2012 | 46.5% | CN¥463.90 Million | CN¥997.86 Million | CN¥889.14 Million | CN¥425.24 Million | ▼ -12.9 pp |
| 2011 | 59.4% | CN¥575.48 Million | CN¥968.71 Million | CN¥711.78 Million | CN¥136.29 Million | ▼ -16.8 pp |
| 2010 | 76.2% | CN¥711.41 Million | CN¥933.05 Million | CN¥922.16 Million | CN¥210.75 Million | ▲ +43.5 pp |
| 2009 | 32.8% | CN¥69.09 Million | CN¥210.67 Million | CN¥253.46 Million | CN¥184.37 Million | ▼ -8.3 pp |
| 2008 | 41.1% | CN¥60.79 Million | CN¥147.93 Million | CN¥293.00 Million | CN¥232.21 Million | ▼ -8.1 pp |
| 2007 | 49.2% | CN¥50.07 Million | CN¥101.70 Million | CN¥131.07 Million | CN¥81.00 Million | — |